Literature DB >> 27734073

Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.

Hervé Quintard1, Delphine Viard, Milou-Daniel Drici, Caroline Ruetsch, Charles Marc Samama, Carole Ichai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27734073     DOI： 10.1160/TH16-06-0445

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  4 in total

1.  The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.

Authors:  Pavel Goriacko; Vicken Yaghdjian; Issam Koleilat; Mark Sinnett; Harshal Shukla
Journal:  P T       Date:  2017-11

2.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

3.  Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

Authors:  Nicolas Gendron; Juliette Gay; Marine Lemoine; Pascale Gaussem; Agnès Lillo-Le-Louet; David M Smadja
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

Review 4.  Reversing factor Xa inhibitors - clinical utility of andexanet alfa.

Authors:  Scott Kaatz; Hardik Bhansali; Joseph Gibbs; Robert Lavender; Charles E Mahan; David G Paje
Journal:  J Blood Med       Date:  2017-09-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.